Technical Analysis for VAL - Valirx Plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 10.75 | -2.27% | -0.25 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| MACD Bullish Centerline Cross | Bullish | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| 50 DMA Support | Bullish | -2.27% | |
| Stochastic Reached Overbought | Strength | -2.27% | |
| Overbought Stochastic | Strength | -2.27% | |
| 20 DMA Support | Bullish | 2.38% | |
| 50 DMA Support | Bullish | 2.38% | |
| Pocket Pivot | Bullish Swing Setup | 2.38% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Gap Down Partially Closed | 2 days ago |
| 5x Volume Pace | 2 days ago |
| 3x Volume Pace | 2 days ago |
| 2x Volume Pace | 2 days ago |
| 1.5x Volume Pace | 2 days ago |
Free Daily (Stock) Chart Reading
Valirx Plc Description
ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Engineering Pharmaceutical Biotechnology Medicine Life Sciences Pipe Disease Clinic Cancer Oncology Clinical Trial Biopharmaceutical Biomarker Drug Development Biomarkers Cancer Screening Chemical Pathology Companion Diagnostic Prostate Cancer Treatment Of Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 32.0 |
| 52 Week Low | 8.675 |
| Average Volume | 588,701 |
| 200-Day Moving Average | 13.05 |
| 50-Day Moving Average | 10.16 |
| 20-Day Moving Average | 9.81 |
| 10-Day Moving Average | 9.88 |
| Average True Range | 0.75 |
| RSI | 58.85 |
| ADX | 16.74 |
| +DI | 21.44 |
| -DI | 15.53 |
| Chandelier Exit (Long, 3 ATRs) | 9.49 |
| Chandelier Exit (Short, 3 ATRs) | 10.94 |
| Upper Bollinger Bands | 11.06 |
| Lower Bollinger Band | 8.55 |
| Percent B (%b) | 0.88 |
| BandWidth | 25.54 |
| MACD Line | 0.03 |
| MACD Signal Line | -0.18 |
| MACD Histogram | 0.2084 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.18 | ||||
| Resistance 3 (R3) | 12.08 | 11.52 | 11.94 | ||
| Resistance 2 (R2) | 11.52 | 11.15 | 11.56 | 11.86 | |
| Resistance 1 (R1) | 11.13 | 10.93 | 11.33 | 11.23 | 11.78 |
| Pivot Point | 10.57 | 10.57 | 10.66 | 10.61 | 10.57 |
| Support 1 (S1) | 10.18 | 10.20 | 10.38 | 10.28 | 9.72 |
| Support 2 (S2) | 9.62 | 9.98 | 9.66 | 9.64 | |
| Support 3 (S3) | 9.23 | 9.62 | 9.56 | ||
| Support 4 (S4) | 9.33 |
